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Protein synthesis and protein degradation are highly regulated cellular processes that are essential to maintaining cell viability.
NumerousstudiesnowindicatethatproteinsynthesisandproteindegradationaresigniﬁcantlyalteredinAlzheimer’sdisease(AD),
withimpairmentsinthesetwoprocessespotentiallycontributingtoADpathogenesis.Alterationsinsteadystateproteinregulation
may be a particularly important factor in regulating whether cells maintain homeostasis in response to oxidative damage, or
conversely whether oxidative stress is induced by oxidative damage. The focus of this review is to discuss recent ﬁndings on each
of these topics, and to discuss their importance to the onset and progression of AD.
Copyright © 2006 Jeﬀrey N. Keller. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Alzheimer’sdiseaseandmildcognitiveimpairment
Alzheimer’s disease (AD) is the leading cause of dementia in
the elderly and is characterized by the presence of extensive
senile plaque deposition and neuroﬁbrillary pathology [10,
20]. Despite the numerous advances in our understanding of
AD, the neurochemical alterations which are responsible for
the onset and progression of AD have not been identiﬁed.
A major obstacle to identifying such factors is the fact that
studies involving AD brain tissue have been diﬃcult to inter-
pret. In particular, it has been diﬃcult to distinguish which
neurochemical events are playing a causal role in mediating
neurodegeneration and neuropathology, and which events
areoccurringinresponsetotheextensiveneurodegeneration
and neuropathology observed in AD brain. Because of this,
there has been considerable interest in conducting studies in
individuals who are in the earliest stages of AD, or individ-
uals who are at the highest risk to develop AD, where the
presence of little-to-no neuropathology allows for a clearer
experimental interpretation of neurochemical studies.
A number of elderly individuals, who do not have de-
mentia, develop cognitive deﬁcits which are atypical of those
observed in normal aging. Longitudinal analysis of these in-
dividuals has demonstrated that they convert to AD at a
much higher rate than the at large elderly population [12,
13]. It is now thought that these individuals may represent a
transitional state between dementia and normal aging, with
such subjects being in the earliest stages of AD pathogenesis
[12, 13]. Neuropathological studies in these individuals have
revealed that these subjects exhibit an extensive overlap with
the autopsy ﬁndings in older cognitively intact individuals.
Because of this, it is believed that these individuals can be
used to identify the neurochemical alterations which occur
in the earliest stages of AD pathogenesis, and neurochemi-
cal alterations which precede the development of dementia
and extensive AD neuropathology. Such neurochemical al-
terations may therefore represent the substrates for patho-
logical and cognitive alterations observed in AD. Individuals
in this cohort are now commonly referred to as having mild
cognitive impairment (MCI) [12, 13].
OxidativedamageinADandMCI
Studies from our laboratory and others have demonstrated
that increased levels of protein oxidation [7, 16], lipid oxida-
tion [14], and nucleic acid oxidation [2, 14] are all evident in
AD. Recent studies have also found that increases in each of
these forms of oxidative damage are present in MCI subjects
[2, 7, 11, 19]. Interestingly, increases in each of these oxida-
tive modiﬁcations preferentially occur in the brain regions
involved in regulating cognition. Such an observation is con-
sistent with oxidative damage contributing to the develop-
ment of dementia. In support of this hypothesis, in studies
involving MCI and early AD subjects the increases in pro-
tein oxidation were observed to be signiﬁcantly and inversely
correlated with word recall performance [7].2 Journal of Biomedicine and Biotechnology
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Figure 1: Interplay between protein synthesis, protein degradation, protein oxidation, and oxidative stress. Oxidized proteins are capable of
inducing oxidative stress, with oxidative stress a potential mediator of AD pathogenesis. The ability of oxidized proteins to induce oxidative
stress is inhibited by protein synthesis and protein degradation pathways. The generation of proteins to replace those which have been
oxidized, and the synthesis of proteins which inhibits oxidized protein toxicity (ie, heat shock proteins), inhibits the induction of oxidative
stress. Proteolytic pathways (lysosomal, proteasomal) degrade oxidized proteins and thereby ameliorate their ability to induce oxidative
stress.
Elevations in oxidative damage in MCI and AD subjects
are signiﬁcantly higher than those of age-matched control
subjects. This suggests that the elevations in oxidative
damage within MCI and AD either represent an acceleration
of the normal age-related generation of oxidative damage, or
may indicate that alternative pathways for the generation of
oxidative damage occur in MCI and AD subjects. Clariﬁca-
tion of this issue is vital to our understanding of AD, and is
likely important for the design of therapeutic interventions
for AD.
It is well established that while elevations in oxidative
damage occur in AD [14, 16], the amount of oxidative dam-
age in an individual does not predict the presence or severity
of AD. This same observation holds true for other age-
related neurodegenerative disorders [3, 6], such as Parkin-
son’sdisease.Thissuggeststhattheabilityofelevatedlevelsof
oxidative damage to induce oxidative stress is not solely de-
pendent upon the gross levels of oxidative damage. It is like-
ly that the development of oxidative stress is regulated in
large part by the ability of cells to replace those macromole-
cules which have been damaged by oxidation, and the ability
of cells to generate suﬃcient levels of inhibitory macromole-
cules, which inhibit the ability of oxidative damage to induce
oxidative stress.
Proteinoxidation,synthesis,anddegradationinAD
While there are many diﬀerent forms of oxidative damage in
AD and MCI, protein oxidation is the one most likely to di-
rectly impact cellular homeostasis. This is based on the fact
that proteins are directly responsible for the various enzy-
matic processes, and structural support, necessary for cellu-
lar homeostasis [17]. Oxidative modiﬁcation of proteins is
capable of inhibiting their normal function, inducing dele-
terious protein fragmentation, and promoting the ability of
proteins to form promiscuous interactions which can lead to
thedevelopmentofproteinaggregates[17].Theformationof
highly oxidized or cross-linked proteins is likely to have neg-
ative eﬀects on the proteolytic pathways (proteasomal and
lysosomal), impairing the ability of these proteases to me-
diate bulk protein turnover [1, 4]. Maintaining low levels of
proteinoxidationisthereforelikelytobeakeyandimportant
partofmaintainingtheoverallsteadystateproteinkineticsin
the cell.
As outlined above, the ability of protein oxidation to in-
ducedeleteriouseﬀectsonacellisultimatelyregulatedbythe
ability of cells to synthesize new proteins. Speciﬁcally, pro-
teins are needed to replace those which have been oxidized,
and to inhibit the initiation of oxidized protein toxicity. Fail-
uretogeneratethesetwotypesofproteinswouldbeexpected
to result in a progressive accumulation of aberrantly func-
tional proteins, which would be expected to have direct and
complex eﬀects on the diﬀerent cells of the brain (Figure 1).
Numerous studies indicate that in both AD and MCI
the levels of protein synthesis are impaired [2, 9]. This in-
hibition appears to be due to deleterious oxidation of RNA
molecules,aswellasgrossdisturbancesoftheribosomecom-
plex [2, 5, 9]. As outlined above, inhibition of protein syn-
thesis would be expected to rapidly exacerbate the ability of
oxidized proteins to induce oxidative stress. For example, the
inability to replace oxidized proteins could increase the per-
centage of inactive or malfunctioning proteins in the cell to a
level suﬃcient to induce cellular stress. Similarly, the thresh-
old of oxidized proteins required to form protein inclusions
and aggregates would be expected to be lower in cells that
are impaired in their ability to synthesize inhibitory pro-
teins (heat shock proteins, proteases). This potentially lethal
combination of increased levels of oxidized proteins, and
decreased levels of protein synthesis, almost certainly con-
tributes to the oxidative stress believed to occur in AD.
It is possible that variability in the inhibition of protein
synthesis helps to explain the inability of gross amounts of
protein oxidation to predict the presence or severity of AD.
For example, cells which have increasing levels of protein ox-
idation but are able to maintain suﬃcient levels of protein
synthesis, there may be no induction of deleterious oxidative
stress. Conversely, in cells wherethere is an inhibition of pro-
teinsynthesisandanincreasingamountofproteinoxidation,
there is likely to be the development of lethal oxidative stress.
Experimental clariﬁcation of each of these issues, including
the identiﬁcation of which proteins are the most important
to inhibiting the ability of oxidative damage to induce oxida-
tive stress, is still very much needed.Jeﬀrey N. Keller 3
Potentialtherapeutics
Based on the aforementioned studies we propose that in-
terventions which increase protein synthesis, in particular
the synthesis of beneﬁcial proteins, may be useful in the
treatment of AD. Two promising classes of pharmaceuticals
are those which inhibit histone deacetylase (HDAC) activ-
ity,andcompoundswhichregulatethemTORpathway.Each
of these types of compounds is known to potently stimu-
late protein synthesis [8, 18], and has been demonstrated
to be neuroprotective. Interestingly, HDAC inhibitors have
been demonstrated to not only suppress oxidative stress tox-
icity in vitro and in vivo, but have also been demonstrated to
suppresstheformationofneuropathology[8,15,18].Identi-
fyingwhichproteinsareincreasedinresponsetotheseexper-
imentaltreatments,andwhichoftheseproteinsareresponsi-
ble for mediating neuroprotection, is important for our un-
derstanding of AD and the generation of potentially useful
interventions for the treatment of AD and other age-related
neurodegenerative disorders.
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